Gynecologic Oncology | Addressing Current Questions and Emerging Considerations with the Use of PARP Inhibitors in the Management of Ovarian Cancer

published 8 months ago by Dr Neil Love

Faculty presentations from an independent satellite symposium during the Society of Gynecologic Oncology’s 2019 Annual Meeting on Women’s Cancer. Featuring perspectives from Dr Robert L Coleman, Prof Jonathan A Ledermann, Dr Stephanie Lheureux and Dr Kathleen Moore: Genomic Testing and Management of Primary Ovarian Cancer — Dr Moore (00:00) Role of PARP Inhibition in the Management of Relapsed Ovarian Cancer — Prof Ledermann (10:37) Prevention, Recognition and Management of PARP Inhibitor-Associated Side Effects — Dr Coleman (21:04) Investigational Applications of Approved PARP Inhibitors; Other PARP Inhibitors in Clinical Development — Dr Lheureux (29:33) Select publications

more episodes from Research To Practice | Oncology Videos